Cargando…
A case of multiple primary lung adenocarcinoma with a CD74‐NRG1 fusion protein and HER2 mutation benefit from combined target therapy
Neuregulin 1 (NRG1) gene fusion is a rare oncogenic driver gene in multiple tumor types, leading to the activation of the epidermal growth factor receptor (ErbB)‐mediated pathway. Therefore, afatinib, a pan‐ErbB family inhibitor, may be a therapeutic candidate for NRG1 fusion‐driven tumors. In this...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626339/ https://www.ncbi.nlm.nih.gov/pubmed/36096509 http://dx.doi.org/10.1111/1759-7714.14636 |